Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (SAGAN)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Biomarker
- Acronyms SAGAN
- 11 Jan 2021 Biomarkers information updated
- 17 Dec 2013 Planned end date changed from 1 Oct 2031 to 1 Jan 2032 as reported by ClinicalTrials.gov.
- 17 Dec 2013 Planned initiation date changed from 1 Oct 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.